Compare Quest Diagnostics Inc (DGX) vs Genuine Parts Company (GPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Genuine Parts Company — how do they compare? Quest Diagnostics Inc trades at $230.72 (market cap $25.48B), while Genuine Parts Company trades at $127.56 (market cap $17.67B). The key difference: Quest Diagnostics Inc is the larger of the two by market cap, and Genuine Parts Company pays the higher dividend (3.32%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Genuine Parts Company for 75 Days on average.
| DGX | GPC | |
|---|---|---|
Market Cap | $25.48B | $17.67B |
Volume | 941,866 | 1,079,458 |
Sector | Health | Consumer Cyclical |
52-Week High | $247.45 | $149.26 |
52-Week Low | $173.49 | $92.47 |
Typical Hold Time | 56 Days | 75 Days |
Enterprise Value | $31.23B | $23.76B |
Dividend Yield | 1.49% | 3.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% on the day, with the stock showing strong fundamental performance including three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.04B in 2025. Technical indicators signal bearish momentum with the current price near key support at $226, while the company maintains solid profitability with 9.19% net income margin and 14.35% ROE. Recent developments include positive clinical study results and a new partnership with Apple Health app for lab testing integration.
The investment outlook remains positive with analyst consensus target of $250 representing 10% upside potential, though Medicare reimbursement cuts pose near-term headwinds. Growth drivers include advanced diagnostics expansion and consumer testing demand, balanced against technical weakness and regulatory uncertainty. The stock offers value with reasonable P/E of 24.1 and consistent dividend payments.
GPC trades at $125.41, down 1.55% today, with a bearish technical signal and neutral oscillators. The company reported mixed quarterly earnings, beating in Q1 and Q2 2026 but missing in Q4 2025, with Q3 2026 results due October 20, 2026. Revenue grew to $24.3B in 2025, but net income margin fell sharply to 0.13%. Analyst consensus is a $145.75 price target with 43% buy ratings. Key developments include the planned spinoff of its industrial unit, Motion, in Q1 2027.
The outlook is cautious due to weak profitability and high P/E, but the spinoff could unlock value. Risks include execution challenges and economic sensitivity. Upside hinges on margin recovery and successful separation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →
